Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

CDKN1A Gene Expression in Two Multiple Myeloma Cell Lines With Different P53 Functionality

DH. Drozdkova, J. Gursky, J. Minarik, I. Überall, Z. Kolar, KS. Trtkova,

. 2020 ; 40 (9) : 4979-4987. [pub] -

Language English Country Greece

Document type Comparative Study, Journal Article

Persistent link   https://www.medvik.cz/link/bmc20024788

BACKGROUND/AIM: Multiple myeloma is a highly heterogeneous disease of clonal plasma cells. Histone deacetylase (HDAC) inhibitors are promising anticancer drugs but their precise mechanisms of actions are not well understood. MATERIALS AND METHODS: Cell-cycle regulation and pro-apoptotic effects of two histone deacetylase inhibitors, suberohydroxamic acid (SAHA) and suberoylanilide hydroxamic acid (SBHA), were analyzed in multiple myeloma cell lines RPMI8226 and U266 with differing TP53 status using gene-expression analysis. RESULTS: Enhanced expression of cyclin-dependent kinase inhibitor 1A (CDKN1A/p21WAF/CIP1) detected in the TP53-deleted U266 cell line after SAHA treatment indicates the P53-independent mode of transcriptional activation of CDKN1A gene. In contrast, CDKN1A gene expression was significantly increased by both SBHA and SAHA treatment of TP53-mutated RPMI8226 cells. CONCLUSION: SAHA appears to be a potentially effective pro-apoptotic and anticancer drug with universal application in the treatment of heterogeneous populations of multiple myeloma cells.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20024788
003      
CZ-PrNML
005      
20201222155956.0
007      
ta
008      
201125s2020 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.14501 $2 doi
035    __
$a (PubMed)32878786
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Drozdkova, Denisa Hrckova $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic denisa.drozdkova@seznam.cz katerina.smesny@upol.cz. Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
245    10
$a CDKN1A Gene Expression in Two Multiple Myeloma Cell Lines With Different P53 Functionality / $c DH. Drozdkova, J. Gursky, J. Minarik, I. Überall, Z. Kolar, KS. Trtkova,
520    9_
$a BACKGROUND/AIM: Multiple myeloma is a highly heterogeneous disease of clonal plasma cells. Histone deacetylase (HDAC) inhibitors are promising anticancer drugs but their precise mechanisms of actions are not well understood. MATERIALS AND METHODS: Cell-cycle regulation and pro-apoptotic effects of two histone deacetylase inhibitors, suberohydroxamic acid (SAHA) and suberoylanilide hydroxamic acid (SBHA), were analyzed in multiple myeloma cell lines RPMI8226 and U266 with differing TP53 status using gene-expression analysis. RESULTS: Enhanced expression of cyclin-dependent kinase inhibitor 1A (CDKN1A/p21WAF/CIP1) detected in the TP53-deleted U266 cell line after SAHA treatment indicates the P53-independent mode of transcriptional activation of CDKN1A gene. In contrast, CDKN1A gene expression was significantly increased by both SBHA and SAHA treatment of TP53-mutated RPMI8226 cells. CONCLUSION: SAHA appears to be a potentially effective pro-apoptotic and anticancer drug with universal application in the treatment of heterogeneous populations of multiple myeloma cells.
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a kontrolní body buněčného cyklu $x účinky léků $7 D059447
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a inhibitor p21 cyklin-dependentní kinasy $x antagonisté a inhibitory $x genetika $7 D050759
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a inhibitory histondeacetylas $x farmakologie $7 D056572
650    _2
$a lidé $7 D006801
650    _2
$a kyseliny hydroxamové $x farmakologie $7 D006877
650    _2
$a mnohočetný myelom $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D009101
650    _2
$a nádorový supresorový protein p53 $x genetika $x metabolismus $7 D016159
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gursky, Jan $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
700    1_
$a Minarik, Jiri $u Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic. Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
700    1_
$a Überall, Ivo $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
700    1_
$a Kolar, Zdenek $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic. Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Trtkova, Katerina Smesny $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic denisa.drozdkova@seznam.cz katerina.smesny@upol.cz. Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 40, č. 9 (2020), s. 4979-4987
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32878786 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155953 $b ABA008
999    __
$a ok $b bmc $g 1598933 $s 1115474
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 40 $c 9 $d 4979-4987 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options